Aim Immunotech【0A4Y】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

買値

0.00

売値

0.00

出来高

0.00

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

0.00

始値

時刻

1106

16.82

(O)

最終取引時間

03:21:33

財務取引量

VWAP

平均取引量 (3 か月)

発行済株式数

48,842,000

配当利回り

PER

-3.04

1 株当たり利益 (EPS)

-0.59

歳入

202k

純利益

-28.96M

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.aimimmuno.com

本社

Wilmington, Delaware, USA

設立

Aim Immunotech Inc is listed in the Biological Pds,ex Diagnstics sector of the ロンドン証券取引所 with ticker 0A4Y. The last closing price for Aim Immunotech was US$0. Over the last year, Aim Immunotech shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Aim Immunotech currently has 48,842,000 shares in issue. Aim Immunotech has a price to earnings ratio (PE ratio) of -3.04.

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Preliminary finding of stable disease in two...

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE...

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen® OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today...

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer Next safety cohort to...

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer OCALA, Fla...

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Year marked by growing body of promising data demonstrating Ampligen’s potential to address...

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM...

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research Data demonstrate...

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties...

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update Company continues progress across Ampligen® clinical development programs Growing body of...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

銘柄コード	株価	出来高
GRLGoldstone Resources Limited	1.80p (26.32%)	2.9M
MKAMkango Resources Ltd	7.55p (21.77%)	3.28M
SLFXSlf Realisation Fund Limited	1.75p (13.64%)	2.2M
QEDQuadrise Plc	2.21p (13.19%)	20.72M
CPXCap-xx Limited	0.1575p (12.50%)	158.35M
HUMHummingbird Resources Plc	1.475p (-28.05%)	19.69M
SCGLSealand Capital Galaxy Limited	0.20p (-27.01%)	24.68M
ECREcr Minerals Plc	0.335p (-19.28%)	68.26M
HEMOHemogenyx Pharmaceuticals Plc	0.98p (-18.33%)	33.1M
BARBrand Architekts Group Plc	23.50p (-16.07%)	153k
NTVONativo Resources Plc	0.0027p (3.85%)	3.6B
TRPTower Resources Plc	0.0265p (-3.64%)	235.17M
UKOGUk Oil & Gas Plc	0.0245p (0.00%)	231.35M
CPXCap-xx Limited	0.1575p (12.50%)	158.35M
DGIDg Innovate Plc	0.086p (4.24%)	122M

銘柄コード

株価

出来高

NTVONativo Resources Plc

0.0027p

(3.85%)

3.6B

TRPTower Resources Plc

0.0265p

(-3.64%)

235.17M

UKOGUk Oil & Gas Plc

0.0245p

(0.00%)

231.35M

CPXCap-xx Limited

0.1575p

(12.50%)

158.35M

DGIDg Innovate Plc

0.086p

(4.24%)

122M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Aim Immunotech Inc (0A4Y)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Aim Immunotech Inc について

0A4Y 最新ニュース

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces Launch of CEO Corner Platform

AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer

AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Aim Immunotech Inc (0A4Y) 銘柄情報

Aim Immunotech Inc (0A4Y)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

Aim Immunotech Inc について

0A4Y 最新ニュース

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE